Concourse Financial Group Securities’s NovoCure NVCR Stock Holding History

Concourse Financial Group Securities’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7	Closed	-$103	–	2344
2023 Q4	$104	Buy	7 +6	+600%	+$80	﹤0.01%	2242
2023 Q3	$16	Sell	1 -74	-99%	-$2.13K	﹤0.01%	2295
2023 Q2	$3.11K	Hold	75	–	–	﹤0.01%	1940
2023 Q1	$4.51K	Hold	75	–	–	﹤0.01%	1895
2022 Q4	$5.5K	Buy	+75	New	+$5.64K	﹤0.01%	1823
2022 Q3	–	Sell	-125	Closed	-$9.75K	–	2206
2022 Q2	$9K	Hold	125	–	–	﹤0.01%	1692
2022 Q1	$10K	Sell	125 -321	-72%	-$23.6K	﹤0.01%	1691
2021 Q4	$33K	Buy	446 +4	+0.9%	+$402	﹤0.01%	1458
2021 Q3	$51K	Buy	442 +233	+111%	+$35.2K	﹤0.01%	1298
2021 Q2	$46K	Hold	209	–	–	﹤0.01%	1349
2021 Q1	$28K	Hold	209	–	–	﹤0.01%	1455
2020 Q4	$36K	Sell	209 -18	-8%	-$2.46K	﹤0.01%	1255
2020 Q3	$25K	Hold	227	–	–	﹤0.01%	1295
2020 Q2	$13K	Hold	227	–	–	﹤0.01%	1430
2020 Q1	$15K	Buy	227 +5	+2%	+$395	﹤0.01%	1339
2019 Q4	$19K	Buy	222 +13	+6%	+$1.05K	﹤0.01%	1269
2019 Q3	$16K	Buy	209 +129	+161%	+$10.3K	﹤0.01%	1030
2019 Q2	$5K	Buy	+80	New	+$4.05K	﹤0.01%	1744

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Concourse Financial Group Securities's NVCR Position: Q1 2024 in Review

Concourse Financial Group Securities sold out of NovoCure (NVCR) in Q1 2024, closing a stake of 7 shares — an estimated $103 sold.

Concourse Financial Group Securities first reported a position in NVCR in Q2 2019 and held it in 18 quarters. The position peaked at $51K in Q3 2021. 238 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

Concourse Financial Group Securities reported no remaining NovoCure position as of Q1 2024 after selling out during the quarter.
Concourse Financial Group Securities sold 7 NovoCure shares in Q1 2024, an estimated $103.
Concourse Financial Group Securities first reported a position in NovoCure in Q2 2019 and held it in 18 quarters.
Concourse Financial Group Securities's NovoCure position peaked at $51K in Q3 2021.
238 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on Concourse Financial Group Securities's 13F filing for Q1 2024, filed 1 May 2024.